OraSure Technologies Inc. (OSUR)
OraSure Technologies Inc. (OSUR) Stock Price, Analysis & Data
| Bid | 2.83 |
| Market Cap | 264.84M |
| Revenue (ttm) | 112.41M |
| Net Income (ttm) | -49.13M |
| Beta | 1.01 |
| EPS (ttm) | -0.69 |
| PE Ratio (ttm) | n/a |
| Forward PE | -5.82 |
| P/B (ttm) | 0.85 |
| P/S (ttm) | 2.36 |
| Earnings Date | Nov 4, 2026 |
| Ask | 4.96 |
| Volume | 582,446 |
| Avg. Volume (20D) | 592,870 |
| Open | 4.02 |
| Previous Close | 4.02 |
| Day's Range | 3.83 - 4.02 |
| 52-Week Range | 2.08 - 4.58 |
| Analyst | Hold |
| Price Target | 4 (4.17%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About OSUR
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen tes...
Financial Performance
In 2025, OraSure's revenue was 115.02M, a decrease of -38.1% compared to the previous year's 185.83M. Earnings were -68.73M, an increase of 252.47%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for OSUR stock is "Hold". The 12-month stock price forecast is 4, which is upside of 4.17% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
